Ocular Therapeutix Inc (OCUL) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a...

Form 144 - Report of proposed sale of securities

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) --  Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the...

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular’s second...

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a...

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the...

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the...